Skip to content

Study of Blood Biomarkers changes before, during, and after surgery in patients with colon cancer

The Role of Metabolomics in Pre-operative,Peri-operative, and Post-operative Phases in Patients with Colon Cancer: A Comparative Analysis of Biomarker changes and short-term clinical outcomes. - nil

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2026/01/100413
Enrollment
36
Registered
2026-01-06
Start date
Unknown
Completion date
Unknown
Last updated
2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C189- Malignant neoplasm of colon, unspecified

Interventions

Intervention1: Nil: Nil Intervention2: Nil: Nil Intervention3: Nil: Nil

Sponsors

kasturba Medical College
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: CASE: Inclusion criteria: All adult patients diagnosed with colon carcinoma , attending Department of Surgical Oncology ,Kasturba Medical College and are scheduled for elective surgery who are willing to give informed consent will be included as cases in study. Controls: Inclusion criteria: Ten consenting age- and sex-matched healthy individuals will be enrolled from Department of Biochemistry. This study group of normal subjects is needed for baseline pilot data collection.

Exclusion criteria

Exclusion criteria: exclusion criteria for case:Colon cancer patients with prior chemotherapy, radiotherapy, or targeted therapy will be excluded. control: Any participant with any chronic metabolic disorders, on drugs which significantly alter metabolism (OHAs, statins, antimetabolites), patients who have undergone surgery/ trauma, pregnant women will be excluded from study.

Design outcomes

Primary

MeasureTime frame
Metabolomic profiling of pre, intra and post-surgical serum profiles in colon cancer patients might help in understanding of tumor specific metabolic reprogramming and post resection metabolic adaptations. Untargeted GC-MS enables identification and fold changes of signature metabolites are characteristic of tumor metabolism. The normalization of these metabolites post-operatively may function as indicators of successful tumor excision, whereas their continued dysregulation could imply incomplete resection or emerging disease recurrence. This metabolic profiling might refine precision oncology through metabolically informed adjuvant therapy selection and monitoring for recurrence.Timepoint: 1-12 months sample collection 12-18 sample processing

Secondary

MeasureTime frame
nilTimepoint: nil

Countries

India

Contacts

Public ContactNithin Kumar U

Kasturba Medical College

unithinm@gmail.com9019800531

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 7, 2026